Clinical Trials Logo

Liver Failure clinical trials

View clinical trials related to Liver Failure.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04229901 Terminated - Clinical trials for Acute on Chronic Liver Failure

Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

DHELIVER
Start date: January 21, 2020
Phase: Phase 2
Study type: Interventional

This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 2 infusions of a 1 dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of infusion.

NCT ID: NCT04160039 Terminated - Liver Failure Clinical Trials

Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit

Start date: November 10, 2019
Phase: N/A
Study type: Interventional

Critically-ill patients with liver disease are at high risk of developing sarcopenia and intensive care unit (ICU)-acquired weakness, which are associated with mortality and other poor outcomes. Early physical rehabilitation has shown benefit in ICU settings, but has not been studied in ICU patients with acute and chronic liver failure. Cycle ergometry, or stationary cycling in passive and active modes, may be especially beneficial to such patients due to their high prevalence of severe physical deconditioning and variable mentation. The aim of this study is to examine the feasibility, safety, and benefit of cycle ergometry over standard physical and occupational therapy (PT/OT) in critically-ill patients who have acute or chronic liver disease.

NCT ID: NCT03860155 Terminated - Clinical trials for Acute-On-Chronic Liver Failure

Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure

Start date: March 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is an interventional, single arm, multicenter, phase I/IIa clinical trial. The study objective is to investigate the efficacy and safety of three i.v. doses of the investigational medicinal product (IMP) allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF). The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

NCT ID: NCT03343756 Terminated - Clinical trials for Acute on Chronic Liver Failure

HepaStem Long-Term Safety Registry

PROLONGSTEM
Start date: April 4, 2018
Phase:
Study type: Observational

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences

NCT ID: NCT03295266 Terminated - Clinical trials for Hepatic Insufficiency

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

Start date: December 19, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, single-dose, Phase 1 study to evaluate the pharmacokinetics (PK) of intravenous (IV) MK-3866 in participants with moderate and severe hepatic impairment (HI) compared to that of matched healthy participants. The primary purpose of this study is to understand the effect of HI on the plasma PK of MK-3866 in order to guide dosing recommendations for participants with HI. This study will also evaluate the safety and tolerability of MK-3866 in participants with moderate and severe HI.

NCT ID: NCT03265249 Terminated - Pain, Postoperative Clinical Trials

BRIDGE Device for Post-operative Pain Control

BRIDGE
Start date: February 12, 2018
Phase: N/A
Study type: Interventional

Auricular neurostimulation is a potential novel and non-invasive method of pain control following liver transplantation in a growing patient population with the probability of significant impact on economics and morbidity. The investigators propose a pilot study to investigate the effects of auricular neurostimulation in patients receiving a liver transplantation. The investigator will investigate the effects of auricular neurostimulation with this novel device and compare it to the current standard of care for pain management following liver transplantation.

NCT ID: NCT02857010 Terminated - Clinical trials for Acute on Chronic Hepatic Failure

Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure

Liveradvance
Start date: February 2016
Phase: Phase 1
Study type: Interventional

Double-blind placebo randomized controlled trial evaluating the clinical efficacy of allogenic bone marrow derived mesenchymal stem cells in cirrhotic patients with acute-on-chronic liver failure

NCT ID: NCT02788240 Terminated - Clinical trials for Acute on Chronic Liver Failure

To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase

Start date: May 1, 2016
Phase: N/A
Study type: Interventional

All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).

NCT ID: NCT02516319 Terminated - Hepatic Failure Clinical Trials

Liver Function Assessment - Feasibility and Dosing Study

Start date: September 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to 1) determine the feasibility of using Cardiox Liver Function Assessment System (LFA) to measure indocyanine green (ICG) clearance; 2) determine an adequate dose based on LFA technology and 3) determine an adequate time period for LFA determination.

NCT ID: NCT02457702 Terminated - Clinical trials for Hepatic Insufficiency

Mitochondrial Function in Patients With Severe Liver Disease

SLDglyc
Start date: October 2015
Phase: N/A
Study type: Interventional

The researchers will recruit patients with liver disease at Parkland Hospital. Patients will fast overnight, and the next morning will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water. The taste is slightly sweet. Blood will be drawn at 60 min and 120 min after the ingestion. Blood glucose will be isolated and analyzed by NMR. The presence of [5,6-13C2]- and [4,5-13C2]glucose indicates preserved mitochondrial function. The researchers anticipate that patients with severe liver disease will show a decrease in mitochondrial function and will inform biosynthetic function of liver mitochondria. After the first 6 successful exams (see power analysis, below), healthy volunteers (age-, gender-, and race-matched) will be studied at the AIRC and subject to the same protocol.